StageZero Life Sciences Ltd
14.3.2022 16:27:02 CET | ACCESS Newswire | Press release
This release replaces and corrects the release that was issued earlier this morning
TORONTO, ON / ACCESSWIRE / March 14, 2022 / StageZero Life Sciences, Ltd. (TSX:SZLS) (OTCQB:SZLSF) ("StageZero" or the "Company"), a vertically integrated healthcare company devoted to improving the early detection and management of cancer and other chronic diseases through leading-edge molecular diagnostics and clinical interventions, announces that the Care Oncology Clinic service and COC Protocol is now available to patients living in Europe. This builds on the availability of the service and program in the UK, the US and Canada.
Care Oncology Clinic provides high quality outpatient treatment in an independent setting with experienced UK and European specialists. The Clinic offers adjunctive treatments that may complement or enhance standard-of-care cancer management. Its patented COC Protocol incorporates a multifaceted approach, supported by peer-reviewed scientific studies, which highlight the potential of certain treatments to target the specific energy requirements of cancer cells, impacting their ability to grow and multiply.
Care is personalized for individual needs and patients receive regular monitoring and support. The service is available both in person at premises in Harley Street, London, UK, and remotely via telemedicine.
"Europe, with a population of approximately 750 million, and a healthcare focus that matches our early detection and management of cancer approach, is a natural extension to our successful Clinics in the UK. We are pleased to continue expanding the availability of our programs geographically and this builds upon our corporate long term growth initiatives of broadening, deepening and expanding our offerings" said James Howard-Tripp, Chairman and CEO of StageZero.
About StageZero Life Sciences, Ltd.
StageZero Life Sciences, Ltd. is a vertically integrated healthcare company dedicated to improving the early detection and management of cancer and other chronic diseases through next-generation diagnostics and unique telehealth programs that provide clinical interventions to assist patients who currently have cancer (COC Protocol) as well as help patients reduce the risk of developing late-stage disease (AVRT™).
The Company's next generation test, Aristotle®, is the first ever mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle® uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. This underlying technology has been validated in more than 9,000 patients and used by more than 100,000 patients in North America.
The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Developed by scientists and oncologists, the COC Protocol is intended for adjunctive administration alongside standard-of-care cancer therapy. It is an individualized therapeutic approach which seeks to simultaneously target multiple metabolic cancer pathways. The aim is to restrict cancer cell energy supply and use, which may make it more difficult overall for cancer cells to survive, grow and adapt to changing conditions in the body. As a result, such cells can potentially become more vulnerable to attack from cell-killing therapies such as radiotherapy and chemotherapy. Its patented COC Protocol incorporates a multifaceted approach, supported by peer-reviewed scientific studies, which highlight the potential of certain treatments to target the specific energy requirements of cancer cells, impacting their ability to grow and multiply.
AVRT is a Physician-Led, telehealth program for identifying and managing the early warning signs of cancer and chronic disease. Our program includes: a comprehensive online health evaluation; blood tests to measure markers of inflammation and metabolism; an in-depth initial physician consultation; regular physician follow-up appointments and interval screening.
Aristotle®, as well as additional cancer diagnostics (ColonSentry®, BreastSentry™, and the Prostate Health Index) are processed at the Company's clinical laboratory, StageZero Life Sciences, Inc., a CAP accredited and CLIA certified high-complexity reference laboratory in Richmond, Virginia. In addition, the Company is also leveraging its specialty in polymerase chain reaction (PCR) testing to provide COVID-19 PCR testing (swab and saliva) and Antibody Testing (blood analysis).
StageZero Life Sciences trades on the Toronto Stock exchange under the symbol SZLS and on the OTCQB under the symbol SZLSF.
Forward-Looking Statements
This press release contains forward-looking statements identified by words such as "expects", "will" and similar expressions, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties that could cause the Company's actual events to differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements, except as required by law.
For further information please contact:
Investor Relations
Rebecca Greco
1-855-420-7140 ext. 1838
rgreco@stagezerols.com
SOURCE: StageZero Life Sciences
View source version on accesswire.com:
https://www.accesswire.com/692951/CORRECTING-AND-REPLACING-StageZero-Life-Sciences-Announces-Availability-of-COC-Protocol-in-Europe
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
MicroVision Brought Onboard by Lake Fusion Technologies and Timberline Aerospace to Accelerate IRIS Sensor Package Deployment16.6.2026 15:20:00 CEST | Press release
Collaboration supports global deployment of advanced situational awareness solutions across commercial, critical infrastructure, security, and government applications REDMOND, WA / ACCESS Newswire / June 16, 2026 / MicroVision, Inc. (NASDAQ:MVIS), a leader in advanced perception solutions for industrial, automotive, security and defense applications, today announced recent shipments of its IRIS lidar sensors to Lake Fusion Technologies (LFT) LLC, as LFT and Timberline Aerospace welcome MicroVision onboard to further expand their collaboration and accelerate the deployment of advanced situational awareness solutions. MicroVision recently shipped IRIS sensors to LFT, marking an important milestone as LFT, together with Timberline Aerospace, brings MicroVision more fully into its ecosystem to broaden capabilities and expedite the development and delivery of integrated IRIS Sensor Packages. The deployment will support LFT's continued development and validation activities as it advances sol
Karbon-X Advances Large-Scale Senegal Blue Carbon Project as Second Globally Registered Under Verra's VM0033 Methodology16.6.2026 15:15:00 CEST | Press release
7,500-hectare Senegal blue carbon initiative achieves Verra registration, marking a significant project development milestone for Karbon-X CALGARY, AB / ACCESS Newswire / June 16, 2026 / Karbon-X Corp. (OTCQB:KARX) ("Karbon-X" or the "Company"), a vertically integrated climate solutions company operating across global carbon markets and climate infrastructure, today announced that its Senegal Blue Carbon Mangrove Project has achieved registration under Verra's Verified Carbon Standard (VCS) and Climate, Community & Biodiversity (CCB) Standards, becoming the second project globally to achieve registration under Verra's VM0033 methodology for tidal wetland and seagrass restoration. Located within Senegal's Sine Saloum Delta and Casamance Estuary regions, the approximately 7,500-hectare project is focused on restoring degraded mangrove ecosystems through reforestation and ecosystem recovery activities. Mangrove forests are among the world's most carbon-rich natural environments, capable o
Leggett Dynamics Launches Smart Brushless Motor & Advances Quiet, Software-Defined Comfort & Motion16.6.2026 13:00:00 CEST | Press release
Reduces Complexity & Cost, Improves Performance, Supports Next-Gen Architectures DETROIT, MI / ACCESS Newswire / June 16, 2026 / Leggett Dynamics today launched its Smart Brushless Motor, a next-generation motion system that simplifies design and vehicle integration, improves NVH and durability and supports evolving software architectures across seating and other motion-control applications. Less Complexity, More Capability Unlike conventional systems, Leggett Dynamics' Smart Brushless Motor can operate with or without a seat-level electronic control unit (ECU), enabling direct communication from the vehicle-level ECU to individual actuators. This streamlined approach supports the industry shift toward more centralized or zonal architectures and enables simplified, scalable integration across multiple seat configurations and trim levels with varying actuator counts. In addition, the motor's design reduces packaging size, weight, and wiring complexity while enhancing sound, durability,
Polaris Renewable Energy Reminds Shareholders to Vote Ahead of Annual Meeting16.6.2026 00:30:00 CEST | Press release
TORONTO, ON / ACCESS Newswire / June 15, 2026 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris" or the "Company") today reminds shareholders to vote their common shares in advance of the Company's upcoming annual meeting of shareholders, which will be held virtually on June 18, 2026 at 9:00 a.m. Toronto time. Shareholders are encouraged to vote as soon as possible and prior to the proxy voting deadline of 9:00 a.m. Toronto time on June 16, 2026. Voting in advance helps ensure that shareholders' shares are represented at the meeting. At the meeting, shareholders will be asked to receive the consolidated financial statements of the Company for the year ended December 31, 2025, together with the report of the auditors thereon. Shareholders will also be asked to vote on the following matters: electing directors of the Company; and reappointing PricewaterhouseCoopers LLP, Chartered Accountants, as auditors of the Company and authorizing the directors of the Company to fix their remunerat
New Pharma AI Findings Reveal the Real Barrier to Scale: Execution, Not Innovation15.6.2026 12:00:00 CEST | Press release
GENEVA, SWITZERLAND AND WARSAW, POLAND / ACCESS Newswire / June 15, 2026 / Pharma companies are no longer struggling to identify AI opportunities - they are struggling to scale them. New findings from Lingaro, based on research with 150 senior pharma and life sciences leaders, show that AI has strong strategic visibility across the sector, yet most organizations lack the foundations needed to turn early momentum into consistent business impact. Nearly 60% of respondents say their AI strategy lacks clear ownership, highlighting a gap between leadership ambition and operational accountability. Without defined business ownership and success metrics, many companies remain stuck between experimentation and scaled delivery. Data is another barrier. According to the research, 67.3% of pharma leaders report fragmented or only partly reliable data. In a sector where commercial, medical, regulatory, and patient data often sit in disconnected systems, poor data quality can delay decisions, reduce
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom